Beta Prograne

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beta Prograne

What is Beta Prograne? An Overview

Property Description
Active Ingredient Propranolol (C16H21NO2)
Form Tablet, Oral solution, Injectable solution
Pharmacological Class Beta-Adrenergic Receptor Blocker (Beta-Blocker)
General Purpose Stabilizing the heart and circulation
Origin Synthetic (man-made compound)

Beta Prograne is a prescription-only synthetic medicine whose therapeutic action is derived entirely from its single active substance, Propranolol. This compound serves as the core active ingredient, making Beta Prograne a single-active ingredient product. The drug is classified as a Beta-Adrenergic Receptor Blocker (or Beta-Blocker), functioning as a non-selective adrenergic antagonist that modulates the body's response to stress hormones. It is clinically recognized for its reliable control over the sympathetic nervous system's signaling pathway and is considered the prototype of its class.

Purpose and Foundational Action

The overall purpose of Beta Prograne is to ease the workload on the cardiovascular system by providing a stabilizing influence against excessive stimulation. The World Health Organization (WHO) includes Propranolol on its Model List of Essential Medicines, confirming its established importance as a crucial cardiovascular medication globally. This effect is achieved through beta-blockade, which helps to sustain a reduction of heart rate and decrease the force of cardiac contraction, thereby limiting the strain on the heart muscle. Beta Prograne is typically supplied as a Tablet for systemic oral delivery, although the availability of the Oral solution and Injectable solution ensures flexibility for various clinical settings.

Regulatory References

  1. Propranolol Overview (StatPearls - NIH)
  2. World Health Organization (WHO)

What side effects are possible with Beta Prograne?

Possible Side Effects and Safety Information

The safety profile of Beta Prograne (Propranolol) is formally classified by regulatory authorities based on the affected system and the frequency of occurrence. Adverse reactions are grouped into categories such as Common, Uncommon, Rare, and Very Rare.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Common Bradycardia (slow heart rate), fatigue, cold extremities, sleep disturbances, and nightmares.
Uncommon Gastrointestinal disturbances, including nausea and vomiting.
Rare Dizziness, paraesthesia, hallucinations, psychoses, visual disturbances, and bronchospasm.

Safety Considerations by System

Adverse effects are documented across several system-organ classes, primarily involving the Cardiovascular System (e.g., hypotension, intensification of AV block) and the Nervous System (e.g., lightheadedness, mental depression).

Serious Adverse Reactions and Risk Context

Regulatory documentation highlights specific, clinically significant reactions, including the precipitation or deterioration of heart failure and severe cutaneous reactions such as Stevens-Johnson Syndrome. The medicine may also mask the clinical signs of hypoglycaemia (low blood sugar), particularly in patients with diabetes or during fasting. An important safety constraint is the documented risk of exacerbation of angina and myocardial infarction following the abrupt discontinuation of treatment, especially in patients with coronary artery disease. Caution is also specified for patients with hepatic or renal impairment due to potential changes in drug elimination.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for Beta Prograne (Propranolol) describes specific clinical manifestations that result from the exaggerated effects of beta-blockade. Officially documented signs of an overdose include profound bradycardia (severely slow heartbeat) and hypotension (critically low blood pressure). Central Nervous System (CNS) effects such as drowsiness and confusion are common and may progress to severe conditions like seizures or coma.

A critical documented metabolic manifestation is hypoglycemia (low blood sugar), which is officially noted as a serious risk, particularly in children, infants, and neonates. Overdose can rapidly lead to life-threatening cardiotoxicity, including advanced heart block, ventricular arrhythmias, and cardiogenic shock.

Due to the potential for rapid progression to severe outcomes, regulatory documents mandate that immediate medical attention must be sought for any suspected overdose. Contact with emergency services is required. Management involves specialized hospital care and includes specific documented supportive measures such as the administration of Glucagon as a pharmacological reversal agent, gastrointestinal decontamination with activated charcoal, and continuous ECG monitoring of the patient's cardiovascular status. These required emergency actions are necessary to manage the severe, label-defined risks of the overdose.

Therapeutic Uses of Beta Prograne

What Beta Prograne Treats: Main Uses and Benefits

Beta Prograne is commonly used across several therapeutic domains to manage symptoms related to heightened physiological activity and cardiovascular stress. It is utilized alone or in combination with other medications, providing symptomatic relief.

The medication helps address symptom clusters that may become intense or disruptive, including those associated with conditions such as high blood pressure (hypertension), chronic stable angina (chest pain), and certain irregular heart rhythms (arrhythmias). It is also commonly used in neurological contexts for the prophylaxis of severe migraine headaches and the management of essential tremor, an involuntary movement disorder. This supportive use contributes to maintaining functional stability.

The therapeutic intent is to ease the overall symptom load during acute or recurrent episodes. This supportive relief may assist with reducing the frequency of episodes or lessening the severity of shaking, allowing patients to cope more steadily with difficult manifestations.

Symptom Focus: Relief for Heightened Heart Rate

Beta Prograne is commonly used to help with symptoms marked by a rapid or forceful heart rate and elevated systemic pressure, which contributes to easing the heart's workload.

Regulatory References

  1. NIH MedlinePlus overview of Propranolol uses

Eligibility and Restrictions for Use

Official Eligibility Rules and Contraindications

The eligibility for Beta Prograne, containing Propranolol, is defined by regulatory documents that mandate absolute exclusions and conditional use in specific populations.

Category Status/Rule (as stated in regulatory sources)
Populations for whom use is allowed Adults for approved indications. Infants aged 5 weeks to 5 months for the specific oral solution formulation (infantile hemangioma)
Populations for whom use is contraindicated Patients with bronchial asthma or a history of bronchospasm. Individuals with cardiogenic shock, severe bradycardia, decompensated heart failure, or second/third degree heart block. Known hypersensitivity to propranolol.
Age-related eligibility rules Contraindicated in premature infants with a corrected age <5 weeks and infants weighing <2 kg (for specific oral solution). Safety and efficacy are not established** for the general pediatric population (children >1 year) for standard formulations.
Condition-specific eligibility rules Use requires caution in patients with hepatic or renal impairment due to altered drug clearance. Diabetic patients require caution as the drug may mask signs of hypoglycemia. Use is limited to patients with controlled heart failure.

The overall eligibility profile is structured by these strict exclusions, which prevent use in patients with severe cardiac conduction issues or respiratory conditions. Eligibility for other populations, such as those with organ impairment, is determined by applying explicit caution or classifying use as not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Beta Prograne (Propranolol) has several officially documented interaction patterns based on regulatory labeling, primarily classified by their effect on heart function or drug exposure.


Pharmacodynamic Interactions and Restrictions

Co-administration with non-dihydropyridine calcium channel blockers, such as Verapamil or Diltiazem, is formally restricted due to the combined risk of severe bradycardia and cardiac depression. Regulatory documents mandate that neither the beta-blocker nor these calcium channel blockers should be administered intravenously within 48 hours of discontinuing the other. The profile also highlights that combining Propranolol with Digitalis Glycosides (Digoxin) may cause an additive slowing of the heart rate. Separately, Propranolol must be discontinued several days before the abrupt withdrawal of Clonidine to prevent a hypertensive crisis.

Pharmacokinetic and Exposure Alterations

Several substances modify the plasma concentration of Beta Prograne. Enzyme inhibitors, including Quinidine and Fluoxetine, increase Propranolol exposure due to reduced metabolism. Conversely, enzyme inducers, such as Rifampin, or substances like cigarette smoking, decrease Propranolol levels, potentially reducing efficacy. Additionally, non-enzyme agents like Cimetidine increase Propranolol concentration, while Antacids containing Aluminum Hydroxide significantly reduce its bioavailability. Propranolol itself is documented to increase the exposure of co-administered medicines, including the anticoagulant Warfarin and the migraine agent Rizatriptan.

Population-Specific Notes

The label includes caution for diabetic patients, noting that Propranolol may mask the tachycardia warning sign of hypoglycemia. It also advises that patients with a history of anaphylaxis may be less responsive to Epinephrine.

Mechanism of Action

Non-Selective Adrenergic Receptor Blockade

Beta Prograne acts as a competitive antagonist on both beta-1 (beta1) and beta-2 (beta2) adrenergic receptors, thereby inhibiting the binding of endogenous catecholamines, such as epinephrine and norepinephrine. This action directly dampens the Sympathetic Nervous System (SNS) signaling pathway.


Cardiac and Renal Pathway Modulation

The blockade of beta1 receptors in the heart reduces the rate and force of contraction, initiating a cascade that lowers cardiac output. Simultaneously, its beta1 action on juxtaglomerular cells in the kidneys suppresses the release of renin, modulating the Renin-Angiotensin-Aldosterone System (RAAS). These combined effects result in a reduction in systemic vascular resistance and blood pressure.


Central and Systemic Sympathetic Dampening

Due to its lipophilic nature, Beta Prograne can cross the blood-brain barrier to modulate beta-adrenergic receptors in the Central Nervous System (CNS), dampening the neurological component of sympathetic outflow. This mechanistic domain results in a reduction of catecholamine-driven responses in the CNS and periphery, altering the physical responses associated with sympathetic activation.

Dosage and Administration Information

Beta Prograne is administered primarily via the oral route through tablets, solutions, or extended-release capsules, with an intravenous route reserved for specific acute clinical needs. The choice of oral form dictates the frequency: immediate-release tablets and solutions require divided doses two to four times daily, while extended-release capsules are taken once daily.

The typical adult daily oral maintenance dosage generally ranges from 80 mg to 240 mg. Treatment is typically initiated with gradual dose titration, where the starting dose is slowly increased over intervals of several days or weeks. Conversely, clinical protocols indicate that the dosage be reduced gradually over a period of a few weeks when discontinuing long-term therapy.

For general administration, immediate-release forms may be taken with or without food, though taking the medicine consistently (always the same way) is advised. Critically, extended-release capsules must be swallowed whole and must not be broken, chewed, or crushed to protect their unique release profile. The oral solution for infants requires weight-based dosing and administration during or right after a feeding. Dose adjustment may be necessary for individuals with hepatic or renal impairment. If a dose is missed, the protocol is to skip the dose and proceed with the next scheduled dose.

Recent Clinical Evidence

The research evidence for Propranolol (the active substance in Beta Prograne) has been established over many years, documented through various types of clinical research to examine patterns, report findings, and identify limitations.


Evidence for use in Cardiovascular and Arrhythmia Conditions

The research landscape for Propranolol in cardiovascular conditions relies on large-scale Randomized Controlled Trials (RCTs) and meta-analyses involving adult populations. These studies explore outcomes related to systemic imbalance, monitoring changes in blood pressure and heart rate, and the frequency of acute chest pain episodes. Studies focusing on post-heart attack management also monitored measures related to all-cause and cardiovascular outcomes. In the context of irregular heart rhythms, trials examined measurements related to heart rate (ventricular response rate) and the frequency of rhythm recurrence. Findings describe consistent patterns related to these physiological changes across the studied populations.


Evidence for use in Migraine Prophylaxis and Essential Tremor

For migraine headache prophylaxis, evidence from placebo-controlled trials explores changes in the frequency, duration, and severity of episodes. Research on the management of essential tremor includes RCTs and cross-over studies that monitored changes in tremor amplitude and functional ability scores. While research provides context, the specific biological mechanism in these non-cardiac conditions is not fully described by the existing evidence.


Long-term Outcomes, Subgroup Data, and Research Gaps

Research exploring long-term outcomes is often limited, meaning sustained measurements after many years of use are not fully established. Additionally, research in special populations remains insufficient; for instance, observational findings related to outcomes like stroke risk have varied between men and women. Data for certain groups, such as older adults with multiple comorbidities, are often uncertain, and comparative evidence against the newest, highly selective medications is lacking across many subgroups.

Key Studies & References

  1. Propranolol Drug Information (MedlinePlus - NIH)
  2. Beta-blocker use after myocardial infarction: A systematic review and meta-regression analysis

Frequently Asked Questions (FAQ)

Common questions about Beta Prograne (FAQ)

Q: Can Beta Prograne be used during pregnancy or breastfeeding?

Regulatory documents classify the drug for use in pregnancy as Category C, which suggests the potential for benefit may outweigh the risk. For breastfeeding, official information indicates the substance is excreted into human milk at low levels. Official guidance suggests that infants may require monitoring for possible signs of beta-blockade if the drug is used by the mother.


Q: What is the risk of dependence or addiction associated with Beta Prograne?

According to official drug classifications, the active substance in Beta Prograne is not designated as a controlled substance. It is also not known to be habit-forming.


Q: Does Beta Prograne contain any sulfa or penicillin ingredients?

Regulatory ingredient lists for the drug indicate it is a synthetic beta-adrenergic receptor blocking agent, also known as Propranolol Hydrochloride. Its chemical structure does not contain ingredients derived from sulfa or penicillin.


Q: Does Beta Prograne interact with alcohol?

Official product information states that alcohol may have additive effects in lowering blood pressure when taken with the drug. Additionally, the combination may increase the common side effects of drowsiness and dizziness.


Q: Is it normal for me to feel anxious or agitated after starting Beta Prograne?

Official safety information does not list anxiety or agitation among the frequency-classified side effects. However, the official documentation does include general psychiatric and nervous system effects, such as hallucinations, psychoses, and sleep disturbances, which are part of a broader category of possible mental and emotional changes.


Q: Is weight change a reported side effect of Beta Prograne?

Weight gain is not among the initial effects listed on the drug’s core label. However, post-marketing data and research have indicated a potential for weight gain may be associated with its long-term use.


Q: Does Beta Prograne have any known interaction with common pain relievers like ibuprofen?

Official drug interaction profiles indicate that combining Beta Prograne with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may reduce the effects of the drug in lowering blood pressure. This is particularly noted with frequent or regular use of the pain reliever.


Q: Can Beta Prograne be crushed, cut, or chewed?

Administration instructions from regulatory sources state that extended-release formulations should not be broken, chewed, or crushed, as regulatory documents state that this action would destroy the unique controlled-release mechanism.


Q: How long does Beta Prograne stay in your system after you stop taking it?

The half-life of the drug depends on the formulation. The immediate-release form is estimated to last eight to eleven hours, while the extended-release form can last up to 24 hours. Complete elimination, or full washout, from the body may take up to five days.


Q: What happens if I accidentally take too much Beta Prograne?

Accidental overdose can cause serious effects like severe bradycardia (slow heart rate), severe hypotension (low blood pressure), breathing problems, and seizures. Anyone experiencing these effects should seek immediate medical attention.


Q: Can Beta Prograne be taken by people with kidney problems?

Official safety constraints state that use requires caution in patients with renal impairment (kidney problems). This is because the drug’s half-life may be increased, which is why an initial dose adjustment may be necessary.


Q: Does Beta Prograne interact with birth control pills?

While oral contraceptives are not always listed specifically on drug labels, regulatory documents note interactions with several substances that affect drug metabolism. Since some oral contraceptives influence these metabolic pathways, there is a potential for altered plasma concentration of the drug.


Q: Is it okay to take supplements or vitamins with Beta Prograne?

General caution is advised regarding taking the drug with all other medications, vitamins, and herbs. Separately, official advice suggests that multivitamins containing minerals may decrease the effects of the drug, and a separation of at least two hours between doses is suggested.


Q: Are there any dietary restrictions or foods to avoid while taking Beta Prograne?

No explicit dietary restrictions are mandated by regulatory agencies. However, official guidance suggests taking the medicine consistently (always the same way, relative to meals). Separately, protein-rich foods have been noted to increase the drug's availability in the body.


Q: What are the most common reasons why a doctor might prescribe Beta Prograne?

The drug is officially indicated for established uses like hypertension, angina, and migraine prophylaxis. Furthermore, its importance is recognized by its inclusion on the World Health Organization's Model List of Essential Medicines.


Q: Is there a generic version of Beta Prograne available?

Yes, the drug’s active substance, Propranolol Hydrochloride, has been approved by the FDA and is available in various generic formulations from multiple manufacturers.


Q: How does the half-life of Beta Prograne compare to similar drugs?

According to official pharmacokinetics data, the half-life of the immediate-release form is generally three to six hours. The extended-release form has a half-life of about 10 hours. This duration can be prolonged in the elderly population.


Q: What level of research evidence supports the use of Beta Prograne for its main indication?

The evidence supporting the drug's main uses relies on large-scale Randomized Controlled Trials (RCTs) and meta-analyses. These studies explore outcomes related to systemic cardiovascular balance, including blood pressure and heart rate changes.


Q: Does Beta Prograne require regular blood tests for monitoring?

While the drug does not always require routine blood tests, regulatory safety information suggests that monitoring may be needed to check for certain unwanted effects. Specific caution and monitoring are noted in official documents for diabetic patients due to the drug’s potential to mask signs of low blood sugar (hypoglycemia).


Q: Does Beta Prograne affect the immune system?

Official regulatory documents do not list immune suppression as a known side effect. However, the drug’s mechanism of action (beta-blockade) influences receptors that also play a role in regulating inflammatory activity and the function of certain immune cells.


Q: Is Beta Prograne used for anxiety or depression?

The drug is formally indicated for several conditions, and some official sources list its use for certain forms of anxiety or anxiety-related rapid heart rate. However, it is important to note that mental depression is formally listed as a rare adverse reaction to the drug, not a purpose of use.


Q: What happens if you stop taking Beta Prograne suddenly?

Official warnings state that abrupt discontinuation of the drug can cause a heightened sensitivity to stress hormones. This carries a documented risk of exacerbation of chest pain (angina) and heart attack (myocardial infarction), especially in patients with coronary artery disease.


Q: Is Beta Prograne considered a long-term or short-term treatment?

Official instructions concerning gradual dosage reduction when discontinuing long-term therapy indicate that extended use is a common treatment pattern for many patients.


Q: How long does it usually take to notice the effects of Beta Prograne?

According to patient information and pharmacokinetics data, the immediate-release form can begin to work in about one to two hours. The intravenous formulation has an even more immediate onset of action.


Q: Is Beta Prograne safe for people over the age of 65?

Official documents indicate the optimal dose is individually determined according to clinical response, as the drug's half-life may be prolonged in the elderly population. Caution is noted for older adults with multiple health conditions.


Q: Is it true that Beta Prograne might interfere with the ability to drive or operate machinery?

Side effects of the drug include dizziness, lightheadedness, and visual disturbances. Official patient advisories note that caution may be necessary when driving or operating machinery until the individual's response to the drug is known.

How should Beta Prograne be stored and disposed of?

How to Store and Dispose of Beta Prograne?

The official requirements for storing Beta Prograne (Propranolol) are governed by the need to maintain the stability of the active ingredient and ensure safety.

Storage and Handling Requirement Regulatory Mandate
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Keep protected from light and moisture, and ensure the container is tightly closed.
Liquid Formulations Do not freeze any oral solution; discard the product two months after first opening the bottle.
Safety The medication must be kept strictly out of the sight and reach of children.

For disposal, the regulatory instruction is to follow local requirements and use a drug take-back program when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed before being placed in household trash. It is strictly advised not to flush this medication down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beta Prograne found in:

A-Z Index: